- by sedlv
- July 7, 2023
Takeda, F-star Sign Potential $1B Immuno-Oncology Agreement
(July 7, 2023) | By Tristan Manalac.
Takeda has entered into a strategic discovery collaboration and licensing agreement with British biotech F-star Therapeutics to develop next-generation and multi-specific antibodies for undisclosed cancer indications, the companies announced Wednesday.
The partners did not reveal how much Takeda paid upfront for the pact but said that F-star will receive research funding from the Japanese multinational for the duration of the collaboration. F-star will also be entitled to potential future development and commercial milestones of up to $1 billion, depending on whether the partnership’s programs reach their milestones.